Skip to main
MPLT

MPLT Stock Forecast & Price Target

MPLT Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MapLight Therapeutics is a promising biopharmaceutical company with a strong focus on developing circuit-specific treatments for central nervous system disorders. The positive results from their Phase 2 IRIS trial and potential sales of $1.5B for their schizophrenia and AD psychosis drug bode well for their future success. With a dedicated team of leaders in psychiatry and neuroscience and a pipeline of potential treatments, MapLight has the potential to make a significant impact in the neuropsychiatry market. However, they will have to navigate potential risks and competition in order to fully capitalize on their innovations.

Bears say

MapLight Therapeutics is heavily reliant on the success of their drug candidate, ML-007C-MA, as their only source of potential revenue. Any delays or setbacks in the clinical trials could significantly impact the company's financials. With data not expected until 2026 and 2027, it will be a few more years before the company can show any tangible results or gain FDA approval. The market for CNS disorders is highly competitive and the company's financials do not currently reflect a strong position in the market, making it a high-risk investment.

MPLT has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MapLight Therapeutics Inc (MPLT) Forecast

Analysts have given MPLT a Strong Buy based on their latest research and market trends.

According to 10 analysts, MPLT has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MapLight Therapeutics Inc (MPLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.